PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS
Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.
“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”
John Mills, Ph.D., co-director, Neuroimmunology Laboratory
OUR DIFFERENCE
News and updates
The latest
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Discover how Mayo Clinic’s nationally recognized Muscle Pathology Laboratory provides unparalleled diagnostic accuracy for rare muscle diseases through decades of experience, specialized testing, and integrated clinical-pathological evaluation.
Supported by Mayo Clinic’s holistic, precision medicine approach, which included advanced genetic insights, access to an emerging therapy, and tailored treatment monitoring, Giana Urse gained the confidence and clarity she needed to pursue her dream of becoming a dog trainer.
Learn how our autoimmune/paraneoplastic evaluation for encephalopathy uses CSF testing to confirm an autoimmune GFAP meningoencephalomyelitis diagnosis.
Autoimmune encephalitis (AE) is a rare but serious condition, and accurate diagnosis is critical. Misdiagnosis can lead to unnecessary treatments, delayed care, and preventable complications.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about how our movement disorders testing can help diagnose testicular cancer-associated paraneoplastic encephalitis.
Learn more about how our testing protocol is useful in the diagnosis of sorbitol dehydrogenase (SORD) deficiency.
Find out how we use glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder.
Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.
Learn how a phenotype-specific autoimmune neurology evaluation diagnosed a treatable autoimmune encephalitis condition that was missed with a traditional paraneoplastic evaluation.